FDA Approved New Monthly Schizophrenia Injection

The agency cleared Teva Pharmaceuticals' WELTRUZA for the treatment of schizophrenia in adults.

Updated on Oct. 10, 2026 in Mental Health

Isometric editorial illustration of a single medical syringe resting on a sterile clinical surface. — The FDA approved Teva Pharmaceuticals' WELTRUZA, a once-monthly injectable treatment for schizophrenia designed to improve patient adherence and simplify medication management. AI Illustration. Upload story photo >

Live Poll

Do you trust that pharmaceutical companies prioritize patient needs when developing new long-term medication treatments?

The U.S. Food and Drug Administration has approved WELTRUZA, a once-monthly subcutaneous injectable for the treatment of schizophrenia in adults. The drug utilizes proprietary technology to deliver olanzapine without the need for loading doses or oral supplementation.

Why it matters

By eliminating the requirement for daily oral medication, this treatment aims to address chronic adherence challenges that frequently lead to patient instability and relapse. It is designed to simplify care for those managing the condition.

The drug, which relies on SteadyTeq copolymer technology for controlled release, will be available in 318 mg, 425 mg, and 531 mg strengths. It is designed for use by a portion of the 2.1 million people in the U.S. currently diagnosed with schizophrenia.

The players

U.S. Food and Drug Administration

The federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs.

Teva Pharmaceuticals

A global pharmaceutical company with corporate locations in Parsippany, N.J., and Tel Aviv, Israel, that specializes in generic and specialty medicines.

The details

WELTRUZA is administered once per month via a subcutaneous injection and requires no post-injection monitoring. This clinical profile distinguishes it from other regimens that may require supplemental oral intake or frequent medical observation.

October 9, 2026: The FDA officially announced the approval of WELTRUZA.
The drug will be available for distribution in the United States in the coming weeks.

Health Landscape

This approval marks a shift toward long-acting injectable formulations that reduce the burden of daily pill adherence in psychiatry. It follows the precedent set by the Phase 3 SOLARIS trial, which validated the safety and efficacy of the steady-release copolymer delivery system.

Patients may find relief in a treatment schedule that removes the need for daily medication adherence. This could reduce the risk of breakthrough symptoms caused by missed doses and simplify the management of their care routine.

The takeaway

This new delivery method offers a significant shift for patients by providing stable, sustained medication release over a full month. Those managing schizophrenia should discuss with their healthcare provider whether this injectable option fits their specific treatment goals.